Webinar: Lower Meritain Clients’ MSK Surgical Spend by Up to 70% with Regenexx Corporate Program

Why Join Us?

Orthopedic diseases cost $980 billion annually and typically make up 20% of health plan spending. Regenexx has created a new medical specialty, Interventional Orthopedics. Using precise image-guided injections of orthobiologics, this treatment replaces the need for up to 70% of elective orthopedic surgeries and saves self-funded plans up to 70% compared to individual orthopedic surgeries.

During this 30 minute educational session with Q&A, Jason Hellickson, of Regenexx Corporate, will join us in hosting a webinar for Meritain Broker Partners that walks through the Regenexx cost-savings program for self-funded employers. Key learning objectives are outlined below.

1. Why is Regenexx growing so rapidly?
2. Understand how Regenexx transforms MSK for self-funded employers.
3. Learn how simple this is to introduce to your clients.
4. The ease of implementing the benefit.
5. Tools to help you introduce Regenexx.
6. Live Q&A session.